value of this tumor marker regarding relapse, metastasis and death in resectable non-small cell lung cancer

CEA and CK19 expression was higher in lung cancer patients than in patients with benign lung diseases and healthy controls.

The serum CEA level appears to be closely associated with the presence of EGFR gene mutations in patients with pulmonary adenocarcinomas.

elevated level of CEA has a strong negative prognostic impact on survival in operated early stage of non-small cell lung cancer

The levels of CEA in pleural effusion and serum of patients with lung cancer were much higher than those with benign lung disease.

CEA was a highly significant predictor of response to therapy and survival in both limited disease and extensive disease small cell lung cancer patients. Normal serum CEA level was associated with improved response rate.

The utility of the tumour markers carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 19-9, carbohydrate antigen 15-3, alpha-fetoprotein and human chorionic gonadotropin for the diagnosis solitary pulmonary nodules, was investigated.

the percentage of lung carcinoma patients remaining unclassifiable by TTF-1/TP63 was twice that of the five-antibody (TRIM29, CEACAM5, SLC7A5, MUC1, and CK5/6) test

Ppreoperative CEA level was a very good predictor of the pathological stage in stage I non-small cell lung cancer.

93.7% of lung cancer sections showed expression of CEA.

CEA level in pleural lavage fluid was significantly correlated with pleural invasion and in non-small-cell lung cancer. 5-year disease-free survival rates were 86.5% for p-CEA 38 ng/g protein.

In patients with non-small cell lung cancer, recurrence-free survival differed most significantly at a preoperative CEA level of 2.5 ng/ml. Preoperative CEA >2.5 ng/ml was identified as an independent risk factor for recurrence.

The colorectal cancer (CRC) neoplastic glands in colon and liver expressed higher amounts of CEA compared with normal colon. CRC neoplastic glands formed in lung expressed low CEA level, but CEA expression was high in areas of tumor necrosis in lung.

Results indicate that CEA and CYFRA 21-1 are reliable serum tumor markers for the diagnosis of lung cancer.

High CEA expression is associated with lung adenocarcinoma-associated cytologically negative pleural effusions.

Overall survival of lung cancer patients was significantly longer in those with normal pre-treatment serum CEA levels than in those with abnormal pre-treatment serum CEA levels.

Elevated serum carcinoembryonic antigen is associated with non-small cell lung cancer.

In the present meta-analysis, preoperative serum CEA overexpression indicates a poor prognosis for patients with non-small cell lung cancer

The serum levels of carcinoembryonic antigen (CEA), nerve cell-specific enolase, and lactate dehydrogenase in 281 patients with small cell lung cancer (SCLC) were analyzed in this study.

Elevation of serum CEA is associated with Non-small Cell lung cancer.

CEA, NSE, CA125 and pro-GRP could serve as biomarkers for SCLC, and CEA and CYFRA21-1 could serve as biomarkers for NSCLC. Pro-GRP, CA125 and CEA were related to the clinical stages of lung cancer

Significant levels of CEA, CYFRA 21-1, NSE, and TSGF were detected in the serum. The amounts found were useful for diagnosing non-small cell lung cancer (NSCLC) patients who depended on the currently limited biomarker development.

Baseline serum CEA levels can serve as predictive factors for the treatment of EGFR-TKI in non-small cell lung cancer patients harboring EGFR mutations.

BALF and serum NSE, CEA, and CYFRA21.1 elevated in lung cancer, which had prompt value for pathology, especially significant for BALF.

Elevated CEA levels during targeted therapy may be a more sensitive predictor of explosive lung adenocarcinoma progression in patients harboring mutant EGFRs compared to traditional imaging methods.

The detection of TK1 combined with that of cytokeratin-19 fragment (CYFRA21-1), CEA or NSE increased the diagnostic value of TK1 for lung squamous cell carcinoma, adenocarcinoma and small cell lung cancer, respectively.

In patients with non-small-cell lung cancer treated with nivolumab, worse pretreatment performance status, and higher carcinoembryonic antigen were associated with inferior progression-free survival.

High CEACAM5 expression is associated with Non-Small-Cell lung Carcinoma.

In nonsmall cell lung cancer Carcinoembryonic antigen (CEA) is a sialyl Lewis x/a carrier and a ligand for Eselectin on endothelial cells.